A Phase 2 interventional study of Psilocybin in Treatment Resistant Depression, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by University Hospital, Ghent · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 6th largest by planned enrollment, is one of 6 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 3 of the 13 other live ones, and was the 16th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre Hospitalier St Anne · Sites in France
Ages 18+
Beersheva Mental Health Center · Sites in Israel
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
University of Texas at Austin · Sites in United States
Ages 22–65
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 19 · Phase 3 3
First in 2019; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 30 across the 25 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 25 have an industry lead sponsor. The 10 most frequent:
University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
University Hospital, Ghent has 2 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
3 of the studies testing psilocybin in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT07183748Beersheva Mental Health CenterPsilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.
The proposed study will assess the safety, feasibility, preliminary results and neurological aspects of psilocybin-assisted psychotherapy in the treatment of hospitalized patients with treatment-resistant depression.
Screening, after signing the ICF, is done in patients newly admitted to the psychiatric service of Ghent University Hospital or patients referred for hospitalization through the outpatient clinic of the psychiatric service of Ghent University Hospital. Involved patients are hospitalized at the Anxiety, Compulsion and Mood Unit for 8 weeks. They will receive add-on treatment with psilocybin-supported psychotherapy in addition to standard treatment (daily group therapies, mainly non-verbal and activating). This consists of a preparatory phase (4 sessions of 1.5 hours before the first psilocybin session and 1 session of 1.5 hours before the second psilocybin session), the psilocybin sessions themselves (2 sessions, week 3 and week 6) and an integration phase (3 sessions of 1.5 hours after each psilocybin session). All sessions occur with the same 2 therapists throughout the entire course. Therapists are trained to provide experiential and systemic psychotherapeutic interventions.
After hospitalization, weekly outpatient follow-up consultations continue until 12 weeks after the last psilocybin session. Subsequently, patients may still agree to a prospective, observational and naturalistic follow-up until 1 year after the last psilocybin session, during which they will be called monthly by a psychiatrist from the research team to inquire about current mental status and any therapies undertaken in the interim.
During the study, patients are required to fill out questionnaires at regular intervals. Video-recordings will be made of certain parts of the preparation and integration sessions, for analysis with the client experience scale (EXP). The morning of each psilocybin session, female patients must provide a blood sample for a pregnancy test. The morning of each psilocybin session, all patients must provide a urine sample for toxicology screening. EEGs are also taken from patients the day before each psilocybin session, the morning of the first integration session after each psilocybin session and 12 weeks after the last psilocybin session (at the last outpatient consultation). At the start and at the end of the hospitalization phase, a semi-structured interview will be conducted with the patient to gauge expectations on the one hand and experiences on the other.
Throughout the study, the patient's partner will be involved. The partner must complete a number of questionnaires at baseline and throughout the study and will have to be present at 3 EEGs. In addition, the partner will also participate in 1 preparatory session and 2 integration sessions. The partner will also be given the opportunity to spend the night of a psilocybin session with the patient in the hospital (rooming-in). At the start and at the end of the hospitalization phase, a semi-structured interview will be conducted with the partner to gauge expectations on the one hand and experiences on the other.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subjects must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead performed at screening.
Exclusion Criteria:
Currently comorbid or previously diagnosed diagnosis of a
Medical diagnosis incompatible with psilocybin treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of 25mg Psilocybin, 3 weeks apart (week 3 and week 6), accompanied by 7,5 hours of preparation sessions and 9 hours of integration sessions.
Drug: Psilocybin
A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
Also known as: PEX010
Incidence and type of Treatment-Emergent Adverse Events
The safety of performing psilocybin-assisted psychotherapy in treatment-resistant depression (TRD) in a hospitalized setting. Adverse Events (AEs) will be classified by the clinical team based on severity, whether they are expected or unexpected and causality.
Time frame: 18 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
Clinician-administered measure of suicidal ideation. Scores range from 0 to 25, with higher scores indicating more severe suicidal ideation.
Time frame: 18 weeks
Recruitment and retention rates.
The feasibility of performing psilocybin-assisted psychotherapy in TRD in a hospitalized setting.
Time frame: 8 weeks (end of hospitalization).
Qualitative data from the semi-structured interviews with the subjects and their partners.
Acceptability of the intervention and procedures for the subjects as assessed through semi-structured interviews.
Time frame: 8 weeks (end of hospitalization).
Montgomery Asberg Depression Rating Scale (MADRS)
A ten-item clinician-rated diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Scoring ranging from 0 to 60, with higher scores indicating greater depressive symptomology.
Time frame: 18 weeks (optional up to 58 weeks).
Quick Inventory of Depressive Symptomatology - Self Rated (QIDS-SR)
A self report measure of depressive symptoms. Scores range from 0 to 27, with lower scores indicating less symptoms of depression.
Time frame: 18 weeks.
State-Trait Anxiety Inventory (STAI)
A self report measure of anxiety symptoms. Scores range from 20 to 80, with higher scores correlating with greater anxiety.
Time frame: 18 weeks.
World Health Organization Quality of Life Inventory-Brief subscale (WHOQOL-BREF)
A self-report measure of quality of life with four subscales: Physical Health, Psychological Health, Social Relationships, and Environment. Scores for each range from 4-20, with higher scores indicating better quality of life.
Time frame: 18 weeks (optional up to 58 weeks).
Maudsley 3-item Visual Analogue Scale (M3VAS)
A self report measure of depressive symptoms using 3 visual analogue scales. Scores range from 0 to 300, with lower scores indicating less symptoms of depression.
Time frame: 18 weeks.
Subjective Emotional Health Visual Analogue Scale (SEHVAS)
Visual Analogue Scale rating the emotional health of the subject as perceived by the partner. Scores range from 0 to 100, with higher scores indicating a better emotional health.
Time frame: 18 weeks.
revised Dyadic Adjustment Scale (RDAS)
A 14-item questionnaire that measures an individual's perceptions of his/her relationship with an intimate partner. Scores range from 0-69, with higher scores indicating higher consensus, satisfaction and cohesion.
Time frame: 18 weeks (optional up to 58 weeks).
Zarit Burden Interview - Short Form (Zarit-12 Burden Scale)
A self-administered 12-item questionnaire that measures the burden of taking care for a close relative. Scores range from 0 to 48, with higher scores indicating a greater burden of care.
Time frame: 18 weeks.
Client Experiencing Scale (EXP)
A 7-item scale assessing the experiential level of the subject. Higher stages indicate higher levels of experiencing.
Time frame: Week 2, 3, 5 and 6.
Mystical Experience Questionnaire (MEQ)
A 30-item questionnaire that measures the mystical quality of an experience. Scores range from 0 to 5, with higher scores indicating a greater mystical quality of the experience.
Time frame: Within 24 hours after each psilocybin session (week 3 and week 6).
Working Alliance Inventory - Short Revised (WAI-SR)
A 12-item questionnaire that measures the quality of the therapeutic relationship. Scores range from 1 to 5, with higher scores indicating better quality of the therapeutic relationship.
Time frame: 8 weeks.
Semi-structured interviews.
Semi-structured interviews with both subjects and their partners, assessing their expectations and experiences.
Time frame: Week 1 and week 8.
EEG: sensor level analysis (power) and source level analysis (functional connectivity through amplitude envelope correlation), both in resting state and during an emotional paradigm.
A method aimed at examining intrinsic networks in the brain to estimate correlations between brain regions.
Time frame: Week 3, week 6, week 18.
Plan to share: Yes
Supporting information: Study protocol, Informed consent form
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Mar 2026, 22 months after the start.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Depressive Disorder, Treatment-Resistant →